ClinicalTrials.Veeva

Menu
D

Dermatologikum Hamburg | Hamburg, Germany

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Upadacitinib
TAK-279
AMG 451
Enbrel
LY3375880
Dupilumab
Rocatinlimab
5-FU
CHS-0214

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 13 total trials

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque p...

Active, not recruiting
Plaque Psoriasis
Drug: TAK-279
Drug: Placebo

The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoria...

Enrolling
Plaque Psoriasis
Drug: TAK-279

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

Trial sponsors

AbbVie logo
Lilly logo
Takeda logo
AbbVie logo
Amgen logo
C
H
Pierre Fabre logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems